All In Biotech

Free tool

FAERS Monitor: Isopto Carpine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 200890 or its brand name (Isopto Carpine, Pilocarpine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,211

Serious

642

53% of reports

Hospitalization

274

Death reported

34

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective132
  • headache97
  • fatigue96
  • pain96
  • eye pain90
  • dyspnoea85
  • nausea77
  • dizziness75
  • diarrhoea74
  • cough68
  • fall67
  • off label use67
  • arthralgia62
  • product dose omission issue56
  • weight increased55

Reports by year received

View as table
YearReports
200417
200520
20066
20075
200815
200935
201043
20118
201214
201318
201415
201516
20167
201729
201840
201977
202093
202168
2022119
2023107
2024140
2025184
2026135

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,948 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal9027.722.72,296
weight increasedSignal554.33.3136
coughSignal684.23.3166
fallSignal673.52.8119
product dose omission issueSignal563.32.689
painSignal962.72.2105
headacheSignal972.72.2104
dizzinessSignal752.62.175
dyspnoeaSignal852.62.185
arthralgiaSignal622.62.060
fatigueSignal962.11.859
diarrhoea742.01.637
drug ineffective1321.71.543
nausea771.71.422
off label use671.31.15

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.